We are live on
!
Find out more
EC
Elmind Capital Portfolio holdings
AUM
$398M
This Fund
S&P 500
This Quarter
Est. Return
+51.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$339M
AUM Growth
–
Cap. Flow
+$288M
Cap. Flow
% of AUM
85.07%
Top 10 Holdings %
Top 10 Hldgs %
68.55%
Holding
34
New
34
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$32.9M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$32.4M |
| 3 |
Viridian Therapeutics
VRDN
|
+$23.5M |
| 4 |
Celldex Therapeutics
CLDX
|
+$22.8M |
| 5 |
CG Oncology
CGON
|
+$20.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Cogent Biosciences
COGT
$5.17B
| $41.6M | 12.27% |
+1,170,740
| New | +$32.9M |
2025 Q4
0 quarters
|
|
|
2
Syndax Pharmaceuticals
SNDX
$1.48B
| $39M | 11.5% |
+1,855,000
| New | +$32.4M |
2025 Q4
0 quarters
|
|
|
3
Viridian Therapeutics
VRDN
$2.07B
| $26.7M | 7.89% |
+858,631
| New | +$23.5M |
2025 Q4
0 quarters
|
|
4
Vera Therapeutics
VERA
$2B
| $24.4M | 7.21% |
+482,500
| New | +$17.1M |
2025 Q4
0 quarters
|
|
|
5
Celldex Therapeutics
CLDX
$2.31B
| $23.5M | 6.93% |
+865,000
| New | +$22.8M |
2025 Q4
0 quarters
|
|
|
6
CG Oncology
CGON
$5.6B
| $20.4M | 6.03% |
+492,500
| New | +$20.4M |
2025 Q4
0 quarters
|
|
7
BioCryst Pharmaceuticals
BCRX
$2.14B
| $16.8M | 4.95% |
+2,150,000
| New | +$15.5M |
2025 Q4
0 quarters
|
|
8
Vaxcyte
PCVX
$11B
| $13.4M | 3.97% |
+291,500
| New | +$13M |
2025 Q4
0 quarters
|
|
9
Beam Therapeutics
BEAM
$2.6B
| $13.2M | 3.9% |
+476,338
| New | +$12.2M |
2025 Q4
0 quarters
|
|
10
Pharvaris
PHVS
$2.17B
| $13.2M | 3.9% |
+475,750
| New | +$11.5M |
2025 Q4
0 quarters
|
|
11
DELISTED
KalVista Pharmaceuticals
KALV
| $12.9M | 3.82% |
+801,300
| New | +$10.6M |
2025 Q4
0 quarters
|
|
12
DELISTED
Dynavax Technologies
DVAX
| $10.5M | 3.09% |
+679,900
| New | +$7.49M |
2025 Q4
0 quarters
|
|
13
Tyra Biosciences
TYRA
$1.35B
| $9.2M | 2.72% |
+350,000
| New | +$6.43M |
2025 Q4
0 quarters
|
|
14
Nurix Therapeutics
NRIX
$2.3B
| $8.73M | 2.58% |
+460,000
| New | +$6.61M |
2025 Q4
0 quarters
|
|
15
Wave Life Sciences
WVE
$646M
| $7.61M | 2.25% |
+447,846
| New | +$4.55M |
2025 Q4
0 quarters
|
|
16
MBX Biosciences
MBX
$2.51B
| $6.65M | 1.96% |
+211,000
| New | +$5.12M |
2025 Q4
0 quarters
|
|
17
Krystal Biotech
KRYS
$9.83B
| $5.42M | 1.6% |
+22,000
| New | +$4.63M |
2025 Q4
0 quarters
|
|
18
United Therapeutics
UTHR
$23.6B
| $5.36M | 1.58% |
+11,000
| New | +$5.12M |
2025 Q4
0 quarters
|
|
19
BioMarin Pharmaceuticals
BMRN
$10.7B
| $4.87M | 1.44% |
+82,000
| New | +$4.46M |
2025 Q4
0 quarters
|
|
20
Relay Therapeutics
RLAY
$3.94B
| $4.54M | 1.34% |
+536,946
| New | +$3.83M |
2025 Q4
0 quarters
|
|
21
Travere Therapeutics
TVTX
$4.9B
| $4.2M | 1.24% |
+110,000
| New | +$3.58M |
2025 Q4
0 quarters
|
|
22
Protagonist Therapeutics
PTGX
$9.37B
| $3.32M | 0.98% |
+38,000
| New | +$3.11M |
2025 Q4
0 quarters
|
|
23
Cullinan Oncology
CGEM
$962M
| $3.21M | 0.95% |
+310,000
| New | +$2.8M |
2025 Q4
0 quarters
|
|
24
Liquidia Corp
LQDA
$2.48B
| $3.1M | 0.92% |
+90,000
| New | +$2.56M |
2025 Q4
0 quarters
|
|
25
CytomX Therapeutics
CTMX
$527M
| $2.98M | 0.88% |
+700,000
| New | +$2.66M |
2025 Q4
0 quarters
|
|
Similar funds
FFS
SFS
SIC
SIAS
HVP
AC
W
CL
Elmind Capital's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Elmind Capital, which disclosed 34 positions worth $339M. Its ten largest holdings account for 69% of the portfolio.
Its largest position is Cogent Biosciences: 1,170,740 shares worth $41.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Elmind Capital's largest Q4 2025 buy was Cogent Biosciences: 1,170,740 shares worth $41.6M.
- Elmind Capital's ten largest holdings make up 69% of its $339M portfolio in Q4 2025.
- Elmind Capital disclosed 34 positions in Q4 2025, its first 13F filing on record.
Based on Elmind Capital's 13F filing for Q4 2025, filed 17 Feb 2026.